Biotech Beat-Down: Alcobra Ltd and Transition Therapeutics Inc.

Alcobra Ltd (NASDAQ:ADHD) and Transition Therapeutics Inc (USA) (NASDAQ:TTHI) are significantly lower today in the wake of disappointing drug data

Jun 24, 2015 at 1:33 PM
facebook X logo linkedin


It's a down day for the broader equities market, as optimism over a debt deal for Greece fades. Meanwhile, among specific equities seeing significant losses in today's trading are biotechnology names Alcobra Ltd (NASDAQ:ADHD) and Transition Therapeutics Inc (USA) (NASDAQ:TTHI), as traders react to a disappointing batch of drug data.

ADHD, for example, is off 14.7% at $7.16, after data showed the company's treatment for Fragile X Syndrome -- a genetic disorder that may cause autism and attention deficit hyperactivity disorder -- failed its mid-stage trial goals. This negative price action is rare for a stock that's nearly doubled in value on a year-to-date basis.

It appears speculators were bracing for a pullback, however. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), ADHD's 10-day put/call volume ratio of 0.69 ranks in the 68th annual percentile. Elsewhere, nearly one-third of Alcobra Ltd's (NASDAQ:ADHD) float is sold short.

Meanwhile, TTHI is taking it on the chin today -- down 74% at $2.39, and fresh off a two-year low of $2.11. Sparking the sell-off are reports the firm's experimental Alzheimer's drug, ELND005, did not meet the primary endpoints of its Phase 2/3 study. The stock is now comfortably in the red on a year-to-date basis, and on track to close at its lowest point since April 2013.

The stock could see some additional headwinds in the near term, should more short sellers climb on board. Short interest rose 6.7% in the two latest reporting periods, but still only accounts for 1.7% of Transition Therapeutics Inc's (NASDAQ:TTHI) total available float.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI